

The Atopic Dermatitis Disease Registry in Japanese Adult Patients with Moderate-to-Severe Atopic Dermatitis (ADDRESS-J): Baseline Characteristics, Treatment History, and Disease Burden

SUPPORTING INFORMATION

Table S1. ADDRESS-J study investigators.

Affiliation	Investigator
Department of Dermatology, Kyoto Prefectural University of Medicine	Norito Katoh
Department of Dermatology, Nippon Medical School	Hidehisa Saeki
Department of Dermatology, Osaka Habikino Medical Center	Yoko Kataoka
Department of Dermatology, Tokyo Teishin Hospital	Takafumi Etoh
Sawada Dermatology Clinic	Shun'ichi Sawada
Mildix Skin Clinic	Minako Yasumoto
Mildix Skin Clinic, Yokohama Medical Center	Yoshiyuki Murakami
Okuda Dermatology Clinic	Tomoki Okuda
Iidabashi Skin Clinic	Shiomi Kawano
Clinique Dermatologique Todoroki	Yoko Todoroki
Queen's Square Medical Center	Tokuya Omi
Itoh Skin Clinic	Yusei Itoh
Maruyama Hifuka Clinic	Ryuji Maruyama
Kohoku Dermatology	Hiroshi Ikeda
Igarashi Dermatology Clinic	Masaru Igarashi
Tsukuda River-City Dermatology Clinic	Katsumi Tanito
Asai Dermatology Clinic	Toshiya Asai
M&M Skincare Clinic	Mineko Suzuki
emi Skin Clinic Shoto	Emi Nakazaki
Kinoshita Skin Clinic	Miwako Kinoshita
Mizutani Dermatology Clinic	Haruko Mizutani
Hamada Clinic	Kazutoshi Hamada
Chitofuna Dermatology Clinic	Toshiya Ebata
Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University	Michihiro Hide
Sugai Dermatology Park Side Clinic	Junichi Sugai
Department of Dermatology, Tokyo Women's Medical University	Naoko Ishiguro
Department of Dermatology, The University of Tokyo Graduate School of Medicine	Tomomitsu Miyagaki
Department of Dermatology, Osaka University Graduate School of Medicine	Saori Itoi-Ochi
Department of Dermatology, Faculty of Medicine, University of Yamanashi	Hiroshi Mitsui
Department of Dermatology, Dokkyo Medical University Saitama Medical Center	Kazumoto Katagiri

Table S2. AD severity (IGA score) by type of study site.

		Number (%)		
		All	Moderate: IGA = 3	Severe: IGA = 4
		300 (100)	220 (100)	80 (100)
Study site	Hospital	137 (46)	80 (36)	57 (71)
	Clinic	163 (54)	140 (64)	23 (29)

IGA, Investigator's global assessment.

Table S3. Allergic comorbidities presented by AD onset and sex.

Comorbidity	Number (%)					
	Total	AD onset			Sex	
		≥ 0 to < 6 years	≥ 6 to < 18 years	≥ 18 years	Male n (%)	Female n (%)
	187	53	60	182	118	
Allergic diseases (except for atopic dermatitis)	149 (79.7)	37 (69.8)	37 (61.7)	127 (69.8)	96 (81.4)	
Allergic rhinitis	108 (57.8)	30 (56.6)	29 (48.3)	9 (4.9)	4 (3.4)	
Food allergy	53 (28.3)	7 (13.2)	6 (10.0)	7 (3.8)	2 (1.7)	
Allergic conjunctivitis	42 (22.5)	15 (28.3)	14 (23.3)	3 (1.6)	6 (5.1)	
Asthma	35 (18.7)	8 (15.1)	12 (20.0)	37 (20.3)	20 (16.9)	
Allergic contact dermatitis	22 (11.8)	4 (7.5)	3 (5.0)	1 (0.5)	0	
Hives	21 (11.2)	5 (9.4)	6 (10.0)	4 (2.2)	7 (5.9)	
Drug allergy	9 (4.8)	4 (7.5)	1 (1.7)	0	3 (2.5)	
Chronic sinusitis	7 (3.7)	1 (1.9)	5 (8.3)	1 (0.5)	2 (1.7)	
Atopic keratoconjunctivitis	5 (2.7)	0	3 (5.0)	3 (1.6)	0	


AD, atopic dermatitis

Table S4: Baseline biomarkers for AD.

Characteristic	N	All	n	Moderate: IGA = 3	n	Severe: IGA = 4
TARC (pg/mL; median [min, max])	58	3489.0 [450, 58677]	19	1565.0 [590, 25750]	39	3943.0 [450, 58677]
Eosinophils (10 ⁹ /L); median [min, max]	35	0.880 [0.11, 3.54]	17	0.575 [0.11, 2.78]	18	1.062 [0.52, 3.54]
IgE (IU/mL; median [min, max])	58	7052.00 [45.0, 66200.0]	21	1908.00 [59.0, 28587.0]	37	8772.00 [45.0, 66200.0]
LDH (IU/L; median [min, max])	63	307.0 [193, 858]	23	275.0 [193, 422]	40	325.5 [193, 858]


LDH, lactate dehydrogenase; NRS, numerical rating scale; POEM, patient-oriented eczema measure; TARC, thymus- and activation-regulated chemokine.

Figure S1. Allergic comorbidities presented by AD onset.



AD, atopic dermatitis

Figure S2. Relationship between biomarkers and IGA (limited data).



IGA, Investigator's Global Assessment; LDH, lactate dehydrogenase; TARC, thymus- and activation-regulated chemokine.